Effect of prolyl-leucyl-glycinamide on blood pressure, heart rate and angiotensin converting enzyme activity in spontaneously hypertensive and Wistar-Kyoto normotensive rats.

Das S, Bhargava HN

General pharmacology1 Jan 1985Cited by 7 (Europe PMC)

PMID2864305DOI10.1016/0306-3623(85)90193-4PepBankPUB-02864305

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In spontaneously hypertensive rats, MIF at 1 mg/kg had no effect on blood pressure after injection.
In plain wordsIn hypertensive rats, MIF‑1 at 1 mg/kg did not change blood pressure.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
No significant changeBlood pressure at low dose
Study
Ratn: not reported in source
Spontaneously hypertensive rats
Outcome group
Blood pressure · Cardiovascular
Studied dose
1 mg/kg · s.c. · 1,4 and 7 hr after injectionAs given in this study (Rat).
Source sentences
Summary
A single s.c. injection of MIF at a lower dose (1 mg/kg) had no effect on the blood pressure of either SH or WKY rats when measured 1,4 and 7 hr after the injection of MIF.
1 context sentence(design, population, supporting numbers)
Summary · context
The effect of melanotropin release inhibiting factor (L-prolyl-L-leucyl-glycinamide, MIF) on blood pressure and heart rate of both spontaneously hypertensive (SH) and age-matched normotensive Wistar-Kyoto (WKY) rats was investigated.
Report a problemFND-0286430501
02AnimalAnimal study (in vivo)Efficacy outcome
In normotensive Wistar-Kyoto rats, MIF at 1 mg/kg had no effect on blood pressure after injection.
In plain wordsIn normotensive rats, MIF‑1 at 1 mg/kg did not change blood pressure.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
No significant changeBlood pressure at low dose
Study
Ratn: not reported in source
Wistar-Kyoto normotensive rats
Outcome group
Blood pressure · Cardiovascular
Studied dose
1 mg/kg · s.c. · 1,4 and 7 hr after injectionAs given in this study (Rat).
Source sentences
Summary
A single s.c. injection of MIF at a lower dose (1 mg/kg) had no effect on the blood pressure of either SH or WKY rats when measured 1,4 and 7 hr after the injection of MIF.
1 context sentence(design, population, supporting numbers)
Summary · context
The effect of melanotropin release inhibiting factor (L-prolyl-L-leucyl-glycinamide, MIF) on blood pressure and heart rate of both spontaneously hypertensive (SH) and age-matched normotensive Wistar-Kyoto (WKY) rats was investigated.
Report a problemFND-0286430502
03AnimalAnimal study (in vivo)Efficacy outcome
In spontaneously hypertensive rats, MIF at 2 or 4 mg/kg significantly lowered blood pressure after injection.
In plain wordsIn hypertensive rats, MIF‑1 at 2 or 4 mg/kg lowered blood pressure.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
DecreaseBlood pressure at higher doses
Study
Ratn: not reported in source
Spontaneously hypertensive rats
Outcome group
Blood pressure · Cardiovascular
Studied dose
2 or 4 mg/kg · s.c. · 4 and 7 hr after injectionAs given in this study (Rat).
Source sentences
Summary
Higher doses of MIF (2 or 4 mg/kg), on the other hand, significantly depressed blood pressure in SH animals at 4 and 7 hr after the drug injection.
1 context sentence(design, population, supporting numbers)
Summary · context
The effect of melanotropin release inhibiting factor (L-prolyl-L-leucyl-glycinamide, MIF) on blood pressure and heart rate of both spontaneously hypertensive (SH) and age-matched normotensive Wistar-Kyoto (WKY) rats was investigated.
Report a problemFND-0286430503
04AnimalAnimal study (in vivo)Efficacy outcome
In normotensive Wistar-Kyoto rats, MIF did not affect blood pressure at the higher doses.
In plain wordsIn normotensive rats, higher MIF‑1 doses did not change blood pressure.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
No significant changeBlood pressure at higher doses
Study
Ratn: not reported in source
Wistar-Kyoto normotensive rats
Outcome group
Blood pressure · Cardiovascular
Studied dose
2 or 4 mg/kg · s.c.As given in this study (Rat).
Source sentences
Summary
However, MIF had no effect on the blood pressure of WKY rats.
2 context sentences(design, population, supporting numbers)
Summary · context
Higher doses of MIF (2 or 4 mg/kg), on the other hand, significantly depressed blood pressure in SH animals at 4 and 7 hr after the drug injection.
Summary · context
The effect of melanotropin release inhibiting factor (L-prolyl-L-leucyl-glycinamide, MIF) on blood pressure and heart rate of both spontaneously hypertensive (SH) and age-matched normotensive Wistar-Kyoto (WKY) rats was investigated.
Report a problemFND-0286430504
05AnimalAnimal study (in vivo)Efficacy outcome
In spontaneously hypertensive rats, none of the MIF doses appreciably affected heart rate.
In plain wordsIn hypertensive rats, none of the MIF‑1 doses appreciably changed heart rate.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
No significant changeHeart rate
Study
Ratn: not reported in source
Spontaneously hypertensive rats
Outcome group
Heart function · Cardiovascular
Studied dose
1, 2 or 4 mg/kg · s.c.As given in this study (Rat).
Source sentences
Summary
None of the doses of MIF had any appreciable effect on the heart rate of either SH or WKY rats.
3 context sentences(design, population, supporting numbers)
Summary · context
A single s.c. injection of MIF at a lower dose (1 mg/kg) had no effect on the blood pressure of either SH or WKY rats when measured 1,4 and 7 hr after the injection of MIF.
Summary · context
Higher doses of MIF (2 or 4 mg/kg), on the other hand, significantly depressed blood pressure in SH animals at 4 and 7 hr after the drug injection.
Summary · context
The effect of melanotropin release inhibiting factor (L-prolyl-L-leucyl-glycinamide, MIF) on blood pressure and heart rate of both spontaneously hypertensive (SH) and age-matched normotensive Wistar-Kyoto (WKY) rats was investigated.
Report a problemFND-0286430505
06AnimalAnimal study (in vivo)Efficacy outcome
In normotensive Wistar-Kyoto rats, none of the MIF doses appreciably affected heart rate.
In plain wordsIn normotensive rats, none of the MIF‑1 doses appreciably changed heart rate.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
No significant changeHeart rate
Study
Ratn: not reported in source
Wistar-Kyoto normotensive rats
Outcome group
Heart function · Cardiovascular
Studied dose
1, 2 or 4 mg/kg · s.c.As given in this study (Rat).
Source sentences
Summary
None of the doses of MIF had any appreciable effect on the heart rate of either SH or WKY rats.
3 context sentences(design, population, supporting numbers)
Summary · context
A single s.c. injection of MIF at a lower dose (1 mg/kg) had no effect on the blood pressure of either SH or WKY rats when measured 1,4 and 7 hr after the injection of MIF.
Summary · context
Higher doses of MIF (2 or 4 mg/kg), on the other hand, significantly depressed blood pressure in SH animals at 4 and 7 hr after the drug injection.
Summary · context
The effect of melanotropin release inhibiting factor (L-prolyl-L-leucyl-glycinamide, MIF) on blood pressure and heart rate of both spontaneously hypertensive (SH) and age-matched normotensive Wistar-Kyoto (WKY) rats was investigated.
Report a problemFND-0286430506
07AnimalAnimal study (in vivo)Mechanism
In spontaneously hypertensive rats, MIF did not change plasma ACE activity after administration.
In plain wordsIn hypertensive rats, MIF‑1 did not change plasma ACE activity.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
No significant changePlasma ACE activity
Study
Ratn: not reported in source
Spontaneously hypertensive rats
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
1, 2 or 4 mg/kg · s.c. · 4 hr after administrationAs given in this study (Rat).
Source sentences
Summary
No change in the ACE activities of central and peripheral tissues (plasma, pituitary, striatum and hypothalamus) of SH rats was observed 4 hr after the administration of MIF (1, 2 or 4 mg/kg), a time at which MIF produced significant antihypertensive effect.
1 context sentence(design, population, supporting numbers)
Summary · context
The effect of melanotropin release inhibiting factor (L-prolyl-L-leucyl-glycinamide, MIF) on blood pressure and heart rate of both spontaneously hypertensive (SH) and age-matched normotensive Wistar-Kyoto (WKY) rats was investigated.
Report a problemFND-0286430507
08AnimalAnimal study (in vivo)Mechanism
In spontaneously hypertensive rats, MIF did not change pituitary ACE activity after administration.
In plain wordsIn hypertensive rats, MIF‑1 did not change pituitary ACE activity.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
No significant changePituitary ACE activity
Study
Ratn: not reported in source
Spontaneously hypertensive rats
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
1, 2 or 4 mg/kg · s.c. · 4 hr after administrationAs given in this study (Rat).
Source sentences
Summary
No change in the ACE activities of central and peripheral tissues (plasma, pituitary, striatum and hypothalamus) of SH rats was observed 4 hr after the administration of MIF (1, 2 or 4 mg/kg), a time at which MIF produced significant antihypertensive effect.
1 context sentence(design, population, supporting numbers)
Summary · context
The effect of melanotropin release inhibiting factor (L-prolyl-L-leucyl-glycinamide, MIF) on blood pressure and heart rate of both spontaneously hypertensive (SH) and age-matched normotensive Wistar-Kyoto (WKY) rats was investigated.
Report a problemFND-0286430508
09AnimalAnimal study (in vivo)Mechanism
In spontaneously hypertensive rats, MIF did not change striatal ACE activity after administration.
In plain wordsIn hypertensive rats, MIF‑1 did not change striatal ACE activity.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
No significant changeStriatal ACE activity
Study
Ratn: not reported in source
Spontaneously hypertensive rats
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
1, 2 or 4 mg/kg · s.c. · 4 hr after administrationAs given in this study (Rat).
Source sentences
Summary
No change in the ACE activities of central and peripheral tissues (plasma, pituitary, striatum and hypothalamus) of SH rats was observed 4 hr after the administration of MIF (1, 2 or 4 mg/kg), a time at which MIF produced significant antihypertensive effect.
1 context sentence(design, population, supporting numbers)
Summary · context
The effect of melanotropin release inhibiting factor (L-prolyl-L-leucyl-glycinamide, MIF) on blood pressure and heart rate of both spontaneously hypertensive (SH) and age-matched normotensive Wistar-Kyoto (WKY) rats was investigated.
Report a problemFND-0286430509
10AnimalAnimal study (in vivo)Mechanism
In spontaneously hypertensive rats, MIF did not change hypothalamic ACE activity after administration.
In plain wordsIn hypertensive rats, MIF‑1 did not change hypothalamic ACE activity.
Peptide
MIF-1 (Pro-Leu-Gly-NH2)
Outcome
No significant changeHypothalamic ACE activity
Study
Ratn: not reported in source
Spontaneously hypertensive rats
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
1, 2 or 4 mg/kg · s.c. · 4 hr after administrationAs given in this study (Rat).
Source sentences
Summary
No change in the ACE activities of central and peripheral tissues (plasma, pituitary, striatum and hypothalamus) of SH rats was observed 4 hr after the administration of MIF (1, 2 or 4 mg/kg), a time at which MIF produced significant antihypertensive effect.
1 context sentence(design, population, supporting numbers)
Summary · context
The effect of melanotropin release inhibiting factor (L-prolyl-L-leucyl-glycinamide, MIF) on blood pressure and heart rate of both spontaneously hypertensive (SH) and age-matched normotensive Wistar-Kyoto (WKY) rats was investigated.
Report a problemFND-0286430510

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.